SWIF Maven Equity Finance invests £750,000 in Tom Parker Creamery

Maven

The British Business Bank’s South West Investment Fund has marked its 100th deal in the region, delivering over £40 million of investment since its launch last year with a £750,000 investment from SWIF Maven Equity Finance into Tom Parker Creamery.

Published: Dec 12, 2024
Focus: SWIF Maven Equity Finance

Founded in 2018, Tom Parker Creamery is a producer of free-range milks and creams from British grass-fed herds. Based at Wincanton in South Somerset, the business produces natural, fully traceable, and sustainable dairy products. The range features free-range milk enriched with vitamins, naturally flavoured milks and cream, all sustainably produced and presented in nostalgic glass bottles.

The company serves several major retailers including Waitrose, Sainsbury’s, Tesco, and Ocado. It has also won various awards including a Great Taste Award (2024), The Farm Shop & Deli Best Product (2024), International Cheese & Dairy Awards; Best Health Drink (2021) and the Great British Food Awards (2022 and 2021).

Investment from SWIF Maven Equity Finance has supported the relocation to a larger facility, allowing for a significant increase in production capacity as the company continues to grow its customer base. The funding will also provide additional working capital, enable the business to increase its headcount and support further product development.

Tom Parker Creamery free ranged whole milk product

“We’re extremely excited to be working with Maven and the South West Investment Fund to help take our business to the second phase of our growth plan. With the current rise in awareness of ultra-processed foods, our range of award-winning products made with free-range British whole milk and natural ingredients mean we’re well positioned to satisfy consumer demands in this area. With this support, the investment enables us to deliver our ambitious plans and meet the rising demands from major retailers and consumers.”

Rob Yates, CEO of Tom Parker Creamery

“Tom Parker Creamery has carved out a unique space in the dairy market, driven by its commitment to high-quality, sustainably sourced products. Rob has built a strong brand, and we’re excited to back him and his team as they scale up and bring their exceptional products to more customers. The South West Investment Fund is there to support businesses just like this to grow whilst making a positive impact on the wider local economy.”

Rafi Khan, Investment Manager at Maven

“We’re thrilled to see the South West Investment Fund make its 100th deal, delivering over £40m of investment since its launch last year. The volume of investments underscores the strength and ambition of growing businesses across the South West, and the critical role of the fund in providing the capital needed for these businesses to innovate, expand, and create lasting impact in their communities. The latest investment in Tom Parker Creamery highlights our commitment to supporting sustainable, growth-oriented businesses in a broad range of sectors across the region.”

Jody Tableporter, Director UK & Regional Funds at the British Business Bank

The purpose of the South West Investment Fund is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the region. The Fund is increasing the supply and diversity of early stage finance for South West smaller businesses, providing funds to firms that might otherwise not receive investment and helping to break down barriers in access to finance.

SWIF – Maven Equity Finance can provide investment of up to £5 million to support ambitious earlier and later stage businesses across the South West of England. To date, the Fund has backed sustainable packaging innovator, Kelpi, global wireless solutions provider Blu Wireless, healthcare buy and build operator, Covestus, Microsoft adoption specialist, Changing Social and leading robotic additive manufacturer, Q5D.

Categories: News

Tags:

Why Platinum Equity Acquired ‘Proud’ Family-Owned Italian Pesto Sauce Producer Polli

Platinum

In 1872, Fausto Polli opened a small store front selling canned vegetables in the heart of Milan.

Since that humble beginning, the Polli family has grown the business to become a leading European producer of pesto and pasta sauces.

The company today operates four plants in which more than 130 different raw materials are processed, producing approximately 29,000 tons of vegetables and more than 190 million packages every year.

A core segment of the business is private label pesto where the company has a leading position in supplying products to European grocery store chains. Traditional pesto is made of basil leaves, pine nuts, garlic and olive oil – simple ingredients considered to be high in healthy fats and antioxidants.

With family eying further international expansion, Platinum Equity recently acquired a majority stake in the company. The Polli family retains a minority stake in the business together with CEO Marco Fraccaroli, who will continue to lead the company.

“Platinum has a lot of experience helping family-owned businesses leverage our M&A capabilities and global operating expertise to capitalize on market opportunities and maximize their potential,” Platinum Equity Co-President Louis Samson said in a released statement after the deal announcement.

“Polli has built an exceptional brand with a proud heritage, and we look forward to working together to build on that legacy.”

Manuela Polli, Managing Director of Polli and sixth generation family member, said: “We are excited to continue our ambitious journey with Platinum Equity, an important partner who shares our company’s values and goals. We are confident that together we will take the business to a new level of global leadership.”

The Polli investment was led by Platinum Equity’s European Small Cap investment team, which is experienced in acquiring businesses in the food and beverage sector.

Samson, Managing Director Fernando Goni and Senior Vice President Filippo Rossi recently gave their thoughts on one of Platinum Equity’s latest investments.

(Questions and answers have been edited for clarity)

Q: Describe the business.

Goni: Polli is a family-owned business that produces pesto sauces and other condiments. The business is mostly for private label, but they also have around 15% of the business which is branded Polli. They make many other products, but it’s mostly a pesto sauce business, selling primarily to large supermarket chains, so very strong in Europe. It’s a company that did extremely well in developing that pesto sauce market.

Samson: This was a family-owned asset for many generations and divesting it was a big decision. With two prior investments (Fantini Group and DeWave), we’re known in Italy and have a track record to stand on. The advisors knew us, and they contacted us on this deal 18 months ahead of it.

The family wasn’t sure initially they wanted to sell a majority share of the business, and it took a while for them to make that decision.

During that time, our team stayed close and developed a very good relationship with the family, especially with Manuela Polli, who’s really driving change and professionalizing the company. We have tremendous respect for the legacy they’ve built and I think over time the family realized that Platinum Equity would be a good home for the business and its next chapter. We have a shared vision to improve the business and grow outside of Italy in Europe and the United States and believe we can help.

Q: For the uninitiated, what is pesto sauce used for?

Goni: It is a very basic sauce that some make themselves or you can buy from the supermarket. It’s basically basil leaves, oil, pine nuts and cheese. It’s not a very complicated product. I live in the U.K. with my family, and we eat it a lot. When we started looking at Polli, I realized I had pesto sauce both in the fridge and in the cupboards.

Rossi: Italians eat it with pasta, but outside of Italy it is a lot more than a pasta sauce. You can mix it with salads and soups. You can put it in sandwiches. It goes on meat and fish as a topping. And it’s interesting that outside of Italy, pesto as a category is growing fast, mainly for its convenience and its flexible usage in vegetarian diets. And that was one of the reasons that we liked the upside potential on the deal.

Q: It’s another instance of Platinum Equity transacting with a family-owned company. Why does the Platinum Equity approach work when it comes to approaching family or founder-owned companies thinking of a possible exit?

Goni: With Polli, it may have been difficult to make a decision to sell because it’s an asset that has been in the family for a long time. I think aligning with the vision of the family is really important. When that alignment exists, I think what Platinum Equity can provide is operational expertise, resources and the ability to grow outside of these European markets. When that aligns with what the family is looking for, then you have a really good match.

Rossi: Every deal has its own history, and it is important to be flexible and provide a solution to the situation that we have in front of us.  With Polli, the family had successfully brought in professional management from the outside already, and performance had been outstanding with CEO Marco Fraccaroli driving the business from approximately € 90 to about € 200 million in revenues. Platinum Equity has helped the company through this generational transition, which is a sensitive topic in Europe.

Q: What will be the operational focus?

Goni: I think that there’s a path of creating more operational efficiencies. I think the other area where we can support them, and there is an opportunity, is on M&A. We’ll look at opportunities, source them, work with the team on executing those deals, integrating those companies. That’s going to be a major part of the deal going forward, and we can definitely team up with them and help on that.

Rossi: We see Polli as a great platform to continue investing in organic growth and also pursue acquisitions both in Europe and the U.S. There is an exciting ambition to establish a direct presence in new geographies or in adjacent fast-growing product categories like dips, snacks, ready-made meals.

Q: Why does Platinum like the food and beverage sector?

Samson:  We’ve made several investments in food and beverage, both in Europe and North America. We like the food and beverage space because it’s quite a stable market. We look at every segment and geography differently, but some of the fundamentals are the same. We really focus on the attributes, and then we see how we can improve the company that we’re buying. But effectively, it’s generally a stable market with typically good growth characteristics. And we like that.

Q: Tell us about Platinum’s strategy in Europe.

Samson: We’ve been in Europe for more than 20 years and we’ve really supercharged the effort in the last eight to ten years. We invested in human capital and infrastructure, and we built a team that has taken us to the degree of relevance and importance in the market that we’ve reached in North America. We didn’t build the team around American transplants into the European market, but instead addressed the European reality by having a multicultural group that understands local culture and speaks the languages, whether it’s Italian, French, Spanish, German, Portuguese, Dutch or English. We have also replicated our full suite of operational and carveout personnel and capabilities on the ground at the European level, which is a hallmark of Platinum’s approach and a big differentiator for us. So far, it’s paying off. We’ve been very active and we like our current position in the market.

 

Categories: News

Tags:

Intended Strategic Stake by VE Partners in Atrium Agri

VE Partners

Atrium Agri B.V., a leading player in high-tech greenhouse construction and technical installations for the global horticultural sector, today announces a proposed strategic partnership with Value Enhancement Partners (VE Partners). VE Partners intends to acquire a stake in Atrium Agri, enhancing the consortium’s focus on innovative solutions within Controlled Environment Agriculture (CEA). The proposed transaction has been submitted to the Dutch Authority for Consumers and Markets (ACM).

With a strong emphasis on sustainability and innovation, the consortium develops integrated solutions for greenhouse construction, automation, water management, and climate control. Atrium Agri operates globally with offices in Europe, China, Australia, North and Central America, and the Middle East.

The collaboration unites Atrium Agri’s impressive portfolio, including renowned brands such as Havecon, Bom Group, VB Group, CambridgeHOK, and Scre3ns for greenhouse construction, screening, and climate solutions, including geothermal energy; and PB tec for technical installations in water, energy, and internal logistics. This enables Atrium Agri to deliver turnkey, bespoke solutions across all continents.

With approximately 375 employees and revenue of €225 million in 2023, Atrium Agri holds a strong market position and the capability to play a leading role in the global transition to sustainable food production.

“This proposed partnership, with significant capital investment, offers us a unique opportunity to accelerate our international growth strategy, both organically and through acquisitions,” said Marck Hagen, CEO of Atrium Agri. “By combining VE Partners’ investment power and expertise with our innovative solutions and ambition, we strengthen our position as a global market leader and take a significant step toward a more sustainable future.”

The completion of this partnership is expected within the next month.

Categories: News

Tags:

Mayapada Healthcare Group Secures $157 Million Strategic Growth Investment from Bain Capital

BainCapital

Source: Mayapada Healthcare Group

Partnership Enables Mayapada Healthcare Group to Drive Innovation, Expand Reach, and Meet Indonesia’s Growing Healthcare Demand

Jakarta – December 12, 2024 – Mayapada Healthcare Group, a leading private premium healthcare provider specializing in multi-disciplinary and specialty care, announced a $157 million strategic growth investment from Bain Capital, a global private investment firm. It demonstrates strong confidence in Mayapada Hospital’s premium healthcare platform, which is well-positioned to meet the growing demand for high-quality care in Indonesia.

The investment be used to further scale access Mayapada Healthcare Group’s hospital platform through organic and strategic growth initiatives.  It will also support its mission to address Indonesia’s increasing demand for high-quality healthcare services, ultimately improving patient outcomes nationwide. This strategic partnership with Mayapada Healthcare Group aligns with Bain Capital’s global expertise in adding value to healthcare providers, including APMG, Estia Health, Grupo NotreDame Intermedica, HCA, and Nichii Gakken.

Founded in 2008, Mayapada Healthcare Group operates a growing network of premium hospitals to meet Indonesia’s increasing demand for high-quality healthcare. With seven hospitals across Indonesia, including a flagship hospital in Jakarta Selatan, the company serves a large part of the nation’s population and particularly in the densely populated island of Java. It prioritizes patient-centric care supported by advanced technology, specialized medical teams, and sustainable practices. Mayapada Healthcare Group has steadily expanded its footprint, adding five hospitals between 2018 and 2024, and currently has a substantial pipeline of brown and greenfield expansion. Committed to improving access to reliable healthcare, the organization continuously develops its facilities to address community needs, delivering safe, high-quality medical services to Indonesians.

“Indonesia faces a growing gap between healthcare supply and demand due to demographic shifts like an aging population and rising affluence,” said Jonathan Tahir, Chairman and Group CEO of Mayapada Healthcare Group. “Mayapada Healthcare Group is dedicated to making reliable, high-quality healthcare accessible to all Indonesians,” Tahir emphasized. “By leveraging technology and empowering our specialists, we aim to improve patient outcomes and set a new standard for innovative healthcare.”

“Bain Capital brings not just resources, but also deep expertise in helping healthcare providers thrive in a rapidly evolving ecosystem. We are excited for this partnership, which is rooted in a shared vision for what healthcare can achieve in Indonesia, ” Tahir concluded.

“Bain Capital is thrilled to partner with Mayapada Healthcare Group, whose mission and growth strategy align well with the evolving needs of Indonesia’s healthcare market,” said Sarit Chopra, Partner and Head of Special Situations, Asia at Bain Capital.  “As the private healthcare market in Indonesia is just beginning to develop, we have deep conviction that Mayapada has already built a strong foundation for continued growth. We’re committed to enhancing it with top talent, systems, and technology and we are eager to apply our global expertise to support Mayapada’s next growth phase.”

The investment was made through Bain Capital’s Special Situations strategy, which oversees over $20bn AUM and has invested $35bn since its inception.

The transaction is subject to regulatory and public shareholders approval, with targeted closing in early 2025.

###

About Bain Capital

Bain Capital, LP is one of the world’s leading private investment firms that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into numerous asset classes including private equity, credit, public equity, venture capital, real estate, life sciences, insurance, and other strategic areas of focus. The firm has offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management.  Bain Capital’s Special Situations strategy offers tailored capital solutions and strategic partnerships, meeting diverse needs across market cycles. With over $20 billion in assets under management, the team uniquely combines credit and equity expertise to deliver both financial and operational value beyond traditional providers. To learn more, visit (http://www.baincapital.com). Follow @BainCapital on LinkedIn and X (Twitter).

About Mayapada Healthcare Group
Mayapada Healthcare Group (PT Sejahteraraya Anugrahjaya Tbk.) (“SRAJ”) is a key business pillar of the Mayapada Group in the healthcare services sector. Mayapada Healthcare Group runs 7 (seven) hospitals with a total capacity of more than 1,000 beds, supported by more than 1,500 medical professionals who are experts in their fields. The seven hospitals of Mayapada Healthcare Group are Mayapada Hospital Tangerang, Mayapada Hospital Jakarta Selatan, Mayapada Hospital Bogor (BMC), Mayapada Hospital Kuningan, Mayapada Hospital Bandung and Mayapada Hospital Nusantara (IKN). Mayapada Hospital Jakarta Selatan obtained JCI accreditation in December 2024 while the other hospitals have the highest levels of accreditation domestically. Mayapada Healthcare Group operates several flagship services ‘Centers of Excellence’ including Tahir Neuroscience Center, Tahir Uronephrology Center, Cardiovascular Center, Gastrohepatology Center, Oncology Center, Orthopedic Center, Obstetrics & Gynecology Center, Pediatric Center, Internal Medicine and Pulmonology Center, Allergy-Immunology Center and the Autoimmune Center which is first and only service center in Indonesia. Mayapada Hospital Group has several projects in the pipeline and plans to operate more than 2,000 beds by 2027.

 Asia / China

 Zhen Trudy Wang

Categories: News

Tags:

Angitia Biopharmaceuticals Announces $120 Million Series C Financing

BainCapital

Source: Angitia Biopharmaceuticals

  • Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
  • Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases
  • Norbert Riedel, Ph.D., will join the Board of Directors

WOODLAND HILLS, Calif. December 11, 2024 – Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the closing of a $120 million Series C financing round. Bain Capital Life Sciences led the financing, with participation from new investor Janus Henderson and existing investors OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. Proceeds from the Series C will support Angitia’s robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.

“The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines.”

Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The Company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.

In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors. A seasoned scientist and biopharmaceutical executive, he brings decades of leadership experience to Angitia. Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals and Eton Pharmaceuticals and is Chairman of the Board of Alcyone Therapeutics. He recently completed his tenure on the board of Cerevel Therapeutics. Dr. Riedel previously founded Aptinyx, Inc. and served as CEO of Naurex, which was acquired by Allergan in 2015. He also held senior roles at Baxter International and Hoechst-Marion Roussel (now Sanofi). Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.

Angitia is enrolling patients in a Phase 2 study in postmenopausal women with AGA2118 (NCT06577935). AGA2115 is being developed for the treatment of OI and is currently in a first-in-human study (NCT06086613). AGA111 is being explored for use in patients undergoing lumbar interbody fusion in a Phase 3 study (NCT06115512).

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team’s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.

Categories: News

Tags:

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

GIlde Healthcare
December 11, 2024
Basel (Switzerland)

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

The new financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025. This includes additional development activities for basimglurant (NOE-101), an mGluR5 negative allosteric modulator currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC); gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering); and NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated:”This latest financing underscores the strong support and confidence from investors in Noema’s vision to treat neuroscience-based conditions. We are thrilled to welcome EQT Life Sciences into this strong syndicate of investors and have Felice join our Board. EQT’s support and expertise alongside our syndicate of investors will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

The Series B extension follows the initial Series B financing of CHF 103 million (USD 112 million) announced on March 2023, and a CHF 54 million (approx. USD 60 million) Series A round in December 2020.

About Noema Pharma
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises. Learn more at www.noemapharma.com.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Ontario Teachers’ Reaches Agreement to Sell Equity Stake in Connexa to CDPQ

Cdpq

Ontario Teachers’ Pension Plan (“Ontario Teachers’”) and CDPQ, a global investment group, today announced that CDPQ will acquire a co-controlling shareholding in Connexa, a leading designer, builder and operator of New Zealand’s most comprehensive mobile tower infrastructure network.

CDPQ is acquiring a 33% stake in Connexa from Ontario Teachers’ as well as Spark New Zealand’s (“Spark”) entire ~17% stake for CAD 745 million (NZ 909 million). Following the conclusion of the transaction, which is subject to New Zealand’s Overseas Investment Office approval and other regulatory filings, Connexa will be co-controlled by Ontario Teachers’ and CDPQ, with each investor holding a 50% stake. Completion is anticipated to occur in the first half of 2025.

Connexa was created in October 2022 when Ontario Teachers’ purchased a majority stake in the passive mobile telecom tower assets of Spark. Connexa subsequently acquired the tower assets of another local mobile network operator, giving it more than 2,400 towers in New Zealand. Under Ontario Teachers’ ownership, the business has grown to over 75 staff, delivered over 80 new sites, adopted innovative engineering solutions and deployed industry-leading digital tools. It has strengthened relationships with all its customers, secured significant new business, and recently acquired Clearspan — to become New Zealand’s largest owner of land under mobile towers.

Jan Brand, Managing Director, Infrastructure, Asia-Pacific at Ontario Teachers’, said: “We are pleased to bring in CDPQ, a likeminded and long-term-oriented investor, as our ownership partner in Connexa. CDPQ’s addition will help unlock additional capital to help us continue to grow the business and maintain its leading position in New Zealand’s mobile tower infrastructure network. We remain committed to Connexa and its strong team and are pleased to see that CDPQ shares our confidence in the business’s long-term prospects.”

Emmanuel Jaclot, Executive Vice President and Head of Infrastructure, at CDPQ said: “We are thrilled to join forces with Ontario Teachers’ to invest in Connexa, a premier mobile network platform with a critical role in facilitating digital connectivity for New Zealanders. This marks CDPQ’s inaugural infrastructure investment in the country and our third investment in mobile networks globally during the past five years. Together, we will bring international sector expertise and long-term capital to support Connexa in delivering its growth strategy.”

Bruce Crane, Executive Managing Director and Head of Asia-Pacific at Ontario Teachers’ added: “Our focus on core markets such as New Zealand is central to creating long-term value across our portfolio in Asia-Pacific. By strategically managing our assets and seeking partnerships with aligned investors, we aim to drive sustainable growth. This approach allows us to capitalize on opportunities in key sectors like infrastructure, positioning Ontario Teachers’ to generate alpha and maximize value for our members.”

Rob Berrill, CEO at Connexa, said: “We want to acknowledge Ontario Teachers’ and Spark’s considerable support over the last two years as Connexa was established and rapidly scaled to become New Zealand’s largest mobile tower infrastructure company. We look forward to continuing to work with Ontario Teachers’ and now also CDPQ as we execute our business strategy and enable a more connected digital future for all New Zealand.”

ABOUT ONTARIO TEACHERS’

Ontario Teachers’ Pension Plan Board (Ontario Teachers’) is a global investor with net assets of CAD 255.8 billion as at June 30, 2024. We invest in more than 50 countries in a broad array of assets including public and private equities, fixed income, credit, commodities, natural resources, infrastructure, real estate and venture growth to deliver retirement income for 340,000 working members and pensioners.

Our more than 450 investment professionals operate in key financial centres around the world and bring deep expertise in a broad range of sectors and industries. We are a fully funded defined benefit pension plan and have earned an annual total-fund net return of 9.3% since the plan’s founding in 1990. At Ontario Teachers’, we don’t just invest to make a return, we invest to shape a better future for the teachers we serve, the businesses we back, and the world we live in. For more information, visit otpp.com and follow us on LinkedIn.

ABOUT CDPQ

At CDPQ, we invest constructively to generate sustainable returns over the long term. As a global investment group managing funds for public pension and insurance plans, we work alongside our partners to build enterprises that drive performance and progress. We are active in the major financial markets, private equity, infrastructure, real estate and private debt. As at June 30, 2024, CDPQ’s net assets totalled CAD 452 billion. For more information, visit cdpq.com, consult our LinkedIn or Instagram pages, or follow us on X.

CDPQ is a registered trademark owned by Caisse de dépôt et placement du Québec and licensed for use by its subsidiaries.

ABOUT CONNEXA

Connexa is Aotearoa New Zealand’s largest specialist mobile tower infrastructure company, operating a nationwide portfolio of more than 2,400 mobile sites. Connexa has an ambitious committed mobile tower build programme to meet New Zealand’s growing demand for wireless digital connectivity. For more information, visit connexa.co.nz or follow us on LinkedIn.

– 30 –

For more information

Categories: News

Tags:

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million

EQT Life Science

Proceeds will be used to enable key late-stage clinical trial readouts for assets across several underserved neurological diseases with high unmet medical need.

EQT Life Sciences has led the extension, and joins a consortium of prominent global biotechnology investors.

The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo, MD

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series B extension brings the total capital raised in the round to CHF 130 million, including prior investments from Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

CNS disorders are a significant area of unmet medical need, affecting hundreds of millions of people worldwide who often face inadequate treatment options with limited effectiveness and significant side effects. Many of the conditions targeted by Noema Pharma have historically been difficult to treat due to their complex nature and the lack of effective therapies. By leveraging its diverse portfolio of neurological assets and innovative clinical pipeline, Noema Pharma is strongly positioned to address these debilitating disorders and provide much-needed hope and transformative solutions to patients living with these life-altering challenges. The Company’s portfolio includes four active Phase 2 trials, with key readouts from all studies anticipated in 2025.

Proceeds from the financing will drive the continued development of Noema Pharma’s clinical-stage assets, including its lead candidate basimglurant (NOE-101), a mGluR5 inhibitor currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC). Additionally, the Company is advancing gemlapodect (NOE-105), a PDE10a inhibitor in Phase 2 for Tourette syndrome and childhood onset fluency disorder (COFD or stuttering), as well as NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and additional symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated: “We are thrilled to welcome EQT Life Sciences as a lead investor and to have Felice join our Board. Their support and expertise will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

Felice Verduyn-van Weegen, Partner at EQT who is joining the Company’s Board of Directors, commented: “Noema Pharma’s innovative approach to CNS disorders aligns very well with our investment strategy and we are excited to support their late-stage clinical pipeline and transformative therapies. Having worked with Ilise Lombardo on a previous successful investment, her exceptional leadership as a repeat entrepreneur further reinforces our confidence in Noema’s potential to deliver meaningful impact to patients in need.”

Contact
EQT Press Office, press@eqtpartners.com

Categories: News

Tags:

Angitia Biopharmaceuticals Announces $120 Million Series C Financing

BainCapital
Source: Angitia Biopharmaceuticals
  • Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
  • Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases
  • Norbert Riedel, Ph.D., will join the Board of Directors

WOODLAND HILLS, Calif. December 11, 2024 – Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the closing of a $120 million Series C financing round. Bain Capital Life Sciences led the financing, with participation from new investor Janus Henderson and existing investors OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. Proceeds from the Series C will support Angitia’s robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.

“The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines.”

Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The Company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.

In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors. A seasoned scientist and biopharmaceutical executive, he brings decades of leadership experience to Angitia. Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals and Eton Pharmaceuticals and is Chairman of the Board of Alcyone Therapeutics. He recently completed his tenure on the board of Cerevel Therapeutics. Dr. Riedel previously founded Aptinyx, Inc. and served as CEO of Naurex, which was acquired by Allergan in 2015. He also held senior roles at Baxter International and Hoechst-Marion Roussel (now Sanofi). Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.

Angitia is enrolling patients in a Phase 2 study in postmenopausal women with AGA2118 (NCT06577935). AGA2115 is being developed for the treatment of OI and is currently in a first-in-human study (NCT06086613). AGA111 is being explored for use in patients undergoing lumbar interbody fusion in a Phase 3 study (NCT06115512).

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team’s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.

 Scott Lessne

Categories: News

Tags:

Carlyle Agrees to Sell 1E to TeamViewer

Carlyle

London, 10 December 2024 – Global investment firm Carlyle (NASDAQ: CG) has agreed to sell 1E, a leader in Digital Employee Experience (“DEX”) software solutions, to TeamViewer SE (TMV.DE) at an enterprise value of $720 million.

1E offers a leading DEX platform that delivers real-time visibility on enterprise IT landscapes. Its products, which identify issues in real-time and automate remediation directly at the endpoint, enable customers to minimise IT downtime, disruptions, and costs, thus enhancing overall IT performance and employee experience. Founded in 1997 and headquartered in London, the business has around 300 employees across the UK, the US, India, and Ireland.

During its ownership period, Carlyle Europe Technology Partners (“CETP”) worked in partnership with 1E’s founder, Sumir Karayi, and the company’s management team led by CEO Mark Banfield to build a high-calibre senior leadership team and deliver on a number of value creation initiatives. This included improving the company’s product and market position as a differentiated DEX leader with an enterprise-grade multi-tenant SaaS product and strong AI capabilities, attracting industry recognition (e.g. as a leader in Gartner’s Magic Quadrant for DEX management tools in August 2024), refining the go-to-market strategy, and driving both commercial momentum and operational efficiencies throughout the business.

Fernando Chueca, Managing Director on the CETP investment advisory team, said: “We are pleased to have supported Mark and his team on the transformation of 1E into a recognized global DEX leader with strong fundamentals. We believe that the business will continue to thrive as part of TeamViewer, building on its position as a full SaaS DEX platform.”

Mark Banfield, CEO of 1E, said: “1E’s driving mission is to create innovative IT solutions that shape the future of work. Together with TeamViewer, we can accelerate that mission by integrating our DEX platform with world-class connectivity solutions. As two companies with truly complementary products and technologies, TeamViewer is the ideal partner to help us scale our offerings and create an intelligent endpoint management leader. I’m excited to join TeamViewer’s management board as we enter this next chapter of our joint growth story. I would also like to thank Carlyle for their partnership and vision over the years. They have been instrumental in helping 1E grow.”

Sumir Karayi, founder of 1E, said: “I am incredibly proud of everything the 1E team have achieved since the business’s origins in 1997. Our leadership position in the DEX market today is a testament to their hard work and dedication. It has been a pleasure to continue working with the business alongside Fernando and the Carlyle team, and I have no doubt it will continue to go from strength to strength as part of TeamViewer.”

The transaction is subject to customary regulatory approvals.

This transaction marks the fourth exit for Carlyle Europe Technology Partners IV and the third signed in the last twelve months, following Work & Co and Jagex.

 

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $447 billion of assets under management as of September 30, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

About 1E

More than 500 organizations in 42 countries trust 1E to help them create a better Digital Employee Experience (DEX). The 1E Platform provides real-time diagnosis, remediation, and automation to proactively fix issues before they ruin the workday. Reduce costs, move faster, and increase employee happiness with 1E. For more information, visit 1E.com.

Media

Carlyle

Nicholas Brown

nicholas.brown@carlyle.com

+44 7471 037 002

1E

Namita Tendolkar

press@1e.com 

Categories: News

Tags: